Exchange: NASDAQ·Updated 07:34 PM EDT
ENLV logo

ENLVEnlivex Therapeutics Ltd

$4.74
$0.09
(1.94%)
Today
Closed $4.73
$0.01
(0.21%)
After Hours
Mkt Cap$78.1M
Vol60,755.00
News
all
press releases
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
More News
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
HC Wainwright Issues Pessimistic Outlook for ENLV Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...
MarketBeat
Research Analysts Set Expectations for ENLV Q1 Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...
MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock
HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...
MarketBeat
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
Enlivex Therapeutics Q4 Earnings Call Highlights
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...
MarketBeat
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS
Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...
MarketBeat
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Press Releases
<
1
2
...
>

Advertisement|Remove ads.